Treatment of Waldenstrom’s Macroglobulinemia With Thalidomide
- 15 August 2001
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (16), 3596-3601
- https://doi.org/10.1200/jco.2001.19.16.3596
Abstract
PURPOSE: We performed a prospective phase II study to assess the activity of thalidomide in patients with Waldenstrom’s macroglobulinemia (WM). PATIENTS AND METHODS: Twenty patients with WM were treated with thalidomide at a starting dose of 200 mg daily with dose escalation in 200-mg increments every 14 days as tolerated to a maximum of 600 mg. All patients were symptomatic, their median age was 74 years, and 10 patients were previously untreated. RESULTS: On an intent-to-treat basis, five (25%) of 20 patients achieved a partial response after treatment. Responses occurred in three of 10 previously untreated and in two of 10 pretreated patients. None of the patients treated during refractory relapse or with disease duration exceeding 2 years responded to thalidomide. Time to response was short, ranging between 0.8 months to 2.8 months. Adverse effects were common but reversible and consisted primarily of constipation, somnolence, fatigue, and mood changes. The daily dose of thalidomide was escalated to 600 mg in only five patients (25%), and in seven patients (35%), this agent was discontinued within 2 months because of intolerance. CONCLUSION: Our data indicate that thalidomide has activity in WM but only low doses were tolerated in this elderly patient population. Confirmatory studies as well as studies that will combine thalidomide with chemotherapy or with rituximab may be relevant.This publication has 18 references indexed in Scilit:
- Thalidomide in the Treatment of Relapsed Multiple MyelomaMayo Clinic Proceedings, 2000
- Thalidomide in patients with advanced multiple myelomaThe Hematology Journal, 2000
- Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myelomaBritish Journal of Haematology, 2000
- Thrombopoietin in the treatment of acute myeloid leukemia and in stem-cell transplantationSeminars in Hematology, 2000
- Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucilBritish Journal of Haematology, 2000
- Thalidomide for resistant and relapsing myelomaSeminars in Hematology, 2000
- Thalidomide — A Revival StoryThe New England Journal of Medicine, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999
- The Spectrum of IgM Monoclonal Gammopathy in 430 CasesMayo Clinic Proceedings, 1987
- Reporting results of cancer treatmentCancer, 1981